Macitentan in daily clinical practice: A single centre, 1-year experience
The effectiveness and safety of macitentan, a dual endothelin-receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH), were shown in an extensive clinical trial oriented towards morbidity and mortality events. Our aim was to describe a single centre's exper...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier España
2018-05-01
|
Series: | Pulmonology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2173511517301495 |
id |
doaj-a29b7e6014484fab8794237c77c7a8e3 |
---|---|
record_format |
Article |
spelling |
doaj-a29b7e6014484fab8794237c77c7a8e32020-11-25T02:52:03ZengElsevier EspañaPulmonology2531-04372018-05-01243170173Macitentan in daily clinical practice: A single centre, 1-year experienceS. Cadenas-Menéndez0P. Álvarez-Vega1J. Martín-Moreiras2M. Barreiro-Pérez3M.Á. Gómez-Sánchez4P.L. Sánchez-Fernández5Pulmonology Service, Pulmonary Hypertension Unit, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain; Corresponding author.Pulmonology Service, Pulmonary Hypertension Unit, Complejo Asistencial Universitario de Salamanca, Salamanca, SpainCardiology Service, Pulmonary Hypertension Unit, Complejo Asistencial Universitario de Salamanca, Salamanca, SpainCardiology Service, Pulmonary Hypertension Unit, Complejo Asistencial Universitario de Salamanca, Salamanca, SpainCardiology Service, Hospital General Nuestra Señora del Prado, CIBER de Enfermedades Respiratorias (CIBERES), Talavera de la Reina, SpainCardiology Service, Pulmonary Hypertension Unit, Complejo Asistencial Universitario de Salamanca, Salamanca, SpainThe effectiveness and safety of macitentan, a dual endothelin-receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH), were shown in an extensive clinical trial oriented towards morbidity and mortality events. Our aim was to describe a single centre's experience of the utilization of macitentan in patients with PAH in clinical practice settings. Thirteen patients with different aetiologies and previous PAH treatments were studied. After 12 months of macitentan treatment, 11 patients improved their functional class (FC), all patients improved their 6-minute walk distance (6MWD) test, and 10 patients lowered their NT-proBNP plasma levels. Additionally, cardiac imaging parameters were also improved. No cases resulted in hospitalization, septostomy, transplant or death. Keywords: Pulmonary arterial hypertension, Macitentan, Endothelin-receptor antagonist, Clinical practice, Phosphodiesterase 5 inhibitors, Prostaglandinshttp://www.sciencedirect.com/science/article/pii/S2173511517301495 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
S. Cadenas-Menéndez P. Álvarez-Vega J. Martín-Moreiras M. Barreiro-Pérez M.Á. Gómez-Sánchez P.L. Sánchez-Fernández |
spellingShingle |
S. Cadenas-Menéndez P. Álvarez-Vega J. Martín-Moreiras M. Barreiro-Pérez M.Á. Gómez-Sánchez P.L. Sánchez-Fernández Macitentan in daily clinical practice: A single centre, 1-year experience Pulmonology |
author_facet |
S. Cadenas-Menéndez P. Álvarez-Vega J. Martín-Moreiras M. Barreiro-Pérez M.Á. Gómez-Sánchez P.L. Sánchez-Fernández |
author_sort |
S. Cadenas-Menéndez |
title |
Macitentan in daily clinical practice: A single centre, 1-year experience |
title_short |
Macitentan in daily clinical practice: A single centre, 1-year experience |
title_full |
Macitentan in daily clinical practice: A single centre, 1-year experience |
title_fullStr |
Macitentan in daily clinical practice: A single centre, 1-year experience |
title_full_unstemmed |
Macitentan in daily clinical practice: A single centre, 1-year experience |
title_sort |
macitentan in daily clinical practice: a single centre, 1-year experience |
publisher |
Elsevier España |
series |
Pulmonology |
issn |
2531-0437 |
publishDate |
2018-05-01 |
description |
The effectiveness and safety of macitentan, a dual endothelin-receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH), were shown in an extensive clinical trial oriented towards morbidity and mortality events. Our aim was to describe a single centre's experience of the utilization of macitentan in patients with PAH in clinical practice settings. Thirteen patients with different aetiologies and previous PAH treatments were studied. After 12 months of macitentan treatment, 11 patients improved their functional class (FC), all patients improved their 6-minute walk distance (6MWD) test, and 10 patients lowered their NT-proBNP plasma levels. Additionally, cardiac imaging parameters were also improved. No cases resulted in hospitalization, septostomy, transplant or death. Keywords: Pulmonary arterial hypertension, Macitentan, Endothelin-receptor antagonist, Clinical practice, Phosphodiesterase 5 inhibitors, Prostaglandins |
url |
http://www.sciencedirect.com/science/article/pii/S2173511517301495 |
work_keys_str_mv |
AT scadenasmenendez macitentanindailyclinicalpracticeasinglecentre1yearexperience AT palvarezvega macitentanindailyclinicalpracticeasinglecentre1yearexperience AT jmartinmoreiras macitentanindailyclinicalpracticeasinglecentre1yearexperience AT mbarreiroperez macitentanindailyclinicalpracticeasinglecentre1yearexperience AT magomezsanchez macitentanindailyclinicalpracticeasinglecentre1yearexperience AT plsanchezfernandez macitentanindailyclinicalpracticeasinglecentre1yearexperience |
_version_ |
1724731684296851456 |